![MDA 19 Size:Solid 10 mg displaced [3H]-rolipram from high-affinity rolipram](https://cdn.shopify.com/s/files/1/0389/1897/9723/products/M10064_1621561266.gif?v=1627980866)
Pay in 4 interest-free payments of $31.50 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
displaced [3H]-rolipram from high-affinity rolipram binding sites and reversed xylazine/ketamine-induced anesthesia
and preferentially eliminated neoplastic cells
is an inhibitor of epidermal growth factor (EGF) receptor kinase with an IC50 value of 460 µM in the human epidermoid carcinoma cell line A431
The comparable efficacy is observed at relatively low doses (10 mg/kg per day)
MDA 19 Size:Solid 10 mg displaced [3H]-rolipram from high-affinity rolipramMDA19 or MDA 19 is discontinued (DEA controlled substance). It is a selective agonist of the human peripheral cannabinoid (CB2) receptor, with an EC50 value for activation (63. 4 nM) that is 14 fold lower than that for central cannabinoid (CB1) activation (EC50 = 867 nM). MDA19 exhibited a distinctive in vitro functional profile at rat CB2 receptors and behaved as a CB1 CB2 agonist in vivo, characteristics of a protean agonist. MDA19 has potential for
US$ 1495.00
US$ 849.50
US$ 9250.00
US$ 445.00
US$ 1245.00
US$ 942.50
US$ 270.00